FY2025 · period end Dec '25 · from the 10-K filed Feb 20, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B |
| Gross Profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B |
| Operating Income | $1.36B | $1.13B | $1.10B | $0.90B | $0.93B |
| Net Income | $1.06B | $0.89B | $0.85B | $0.68B | $0.74B |
| EPS (Diluted) | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $3.35B | $3.29B | $3.26B | $2.75B | $2.44B |
| Total Liabilities | $1.75B | $1.70B | $1.78B | $2.14B | $1.75B |
| Stockholders' Equity | $1.61B | $1.60B | $1.48B | $0.61B | $0.69B |
| Cash & Equivalents | $0.18B | $0.29B | $0.45B | $0.11B | $0.14B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.18B | $0.93B | $0.91B | $0.54B | $0.76B |
| Capital Expenditures | $0.12B | $0.12B | $0.13B | $0.15B | $0.12B |
| Free Cash Flow | $1.06B | $0.81B | $0.77B | $0.39B | $0.64B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% |
| Operating Margin | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% |
| Net Margin | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% |
| Return on Equity | 66.2% | 57.7% | 80.7% | 104.6% | 112.6% |
| Return on Assets | 31.9% | 27.1% | 28.1% | 26.2% | 31.5% |
| Debt / Equity | 0.33× | 0.39× | 0.47× | 1.26× | 1.23× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000874716-26-000110 | May 12, 2026 | May 15, 2026 | May 15, 2026 20:00 UTC | EDGAR |
| 10-Q | 0000874716-26-000076 | Mar 31, 2026 | May 5, 2026 | May 5, 2026 20:14 UTC | EDGAR |
| 8-K | 0001104659-26-055203 | May 5, 2026 | May 5, 2026 | May 5, 2026 10:31 UTC | EDGAR |
| 8-K | 0001104659-26-034906 | Mar 24, 2026 | Mar 26, 2026 | Mar 26, 2026 12:30 UTC | EDGAR |
| 10-K | 0000874716-26-000038 | Dec 31, 2025 | Feb 20, 2026 | Feb 20, 2026 21:09 UTC | EDGAR |
| 8-K | 0000874716-26-000007 | Feb 13, 2026 | Feb 13, 2026 | Feb 13, 2026 22:00 UTC | EDGAR |
| 8-K | 0001104659-26-008904 | Feb 2, 2026 | Feb 2, 2026 | Feb 2, 2026 11:39 UTC | EDGAR |
| 8-K | 0001104659-26-003103 | Jan 11, 2026 | Jan 13, 2026 | Jan 13, 2026 13:33 UTC | EDGAR |
Direct links to SEC EDGAR. IDXX has additional filings available on the SEC site.
6 numbers IDEXX LABORATORIES INC /DE later changed — same XBRL tag, both filings linked.
Net Cash Provided by (Used in) Operating Activities·FY 2012
Notable restatementwas$230.3M
Revised down in a 10-K. Any P/OCF built on the original was 3.5% too low.
Net Cash Provided by (Used in) Operating Activities·Q2 2013
Notable restatementwas$100M
Revised up in a 10-Q. Any P/OCF built on the original was 2.4% too high.
Net Cash Provided by (Used in) Operating Activities·Q1 2013
Minor restatementwas$20.7M
Revised up in a 10-Q. Any P/OCF built on the original was 1.8% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2011
Minor restatementwas$220.7M
Revised down in a 10-K. Any P/OCF built on the original was 1.3% too low.
Net Cash Provided by (Used in) Investing Activities·FY 2012
Major restatementwas-$66M
Revised up in a 10-K.
Net Cash Provided by (Used in) Investing Activities·Q2 2013
Notable restatementwas-$40.9M
Revised down in a 10-Q.
IDXX is not the only one.
See every restatement we've found across the market — or get an alert the next time IDXX revises a number.
Restatements are detected by comparing every vintage of a fact across all of IDEXX LABORATORIES INC /DE's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows IDXX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling IDEXX LABORATORIES INC /DE — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on IDXX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on IDXX and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs